Line 425: | Line 425: | ||
<div class="col-full"> | <div class="col-full"> | ||
<h3 class="subhead"></h3> | <h3 class="subhead"></h3> | ||
− | <h1 class="display-2"> | + | <h1 class="display-2">Refrences & Attributions</h1> |
</div> | </div> | ||
</div> | </div> |
Revision as of 22:05, 15 October 2018
Alternative Roots
Endophytic Chassis Results
Introduction
The first steps in developing Pseudomonas sp. (CT 364) involve identifying antibiotics active that it is susceptible to in order to select transformants and optimistaion of transformation protocols. Five antibiotics were tested and two were found to be active against Pseudomonas sp. Working concentrations were identified for each antibiotic using lab automation. Additionally, a new streptomycin resistance cassette was constructed to be used in building plasmids for Pseudomonas sp.
Antibiotic Testing
Pseudomonas sp. (CT 364) was obtained from DSMZ, Germany (DSM No.: 25356). The strain arrived freeze-dried and was revived according to the protocol recommended by DSMZ(Figure 1).
Screening on tryptone soy agar (TSA) showed Pseudomonas sp. to be resistant to chloramphenicol, kanamycin and carbenicillin. Antibiotic concentrations of 50 and 100 µg/ml were tested with lawns forming on agar containing 100 µg/ml of each antibiotic. (Figures 2, 3 & 4) after 24 hours incubation at 28 °C.
Screening on TSA showed that Pseudomonas sp. was susceptible to both streptomycin (Figure 5) and gentamicin (Figure 6) with no colony forming units (CFUs) visible on agar containing 50 µg/ml of either antibiotic after 24 hours incubation at 28 °C.
After identifying which antibiotics were active against Pseudomonas sp. The next step was to identify working concentrations of these antibiotics to be used when selecting transformants. This was done by carrying out minimum inhibitory concentration (MIC) experiments where growth was tested against a range of antibiotic concentrations.
The results of our MIC experiments showed a clear dose response between antibiotic concentration and growth of Pseudomonas sp. for both streptomycin and gentamicin (Figures 7 and 8). Gentamicin was found to be the more effective antibiotic with a concentration of 1.5 µg/ml sufficient to prevent growth. A concentration of 6.0 µg/ml of streptomycin was required to prevent growth. A slight increase in absorbance was observed for the positive control for both antibiotics. This is likely due to release of compounds by bacterial cells upon death.
After identifying the MIC in liquid culture, the MICs in agar were determined for gentamicin as this was the antibiotic being taken forward for transformation.
Agar assays showed that concentrations of 2 µg/ml and 4 µg/ml of antibiotic were insufficient to prevent growth of Pseudomonas sp. on agar with a lawn forming on 2 µg/ml and some colonies forming on 4 µg/ml (Figure 9). A gentamicin concentration of 6 µg/ml was sufficient to prevent growth of Pseudomonas sp. as no colonies formed at this concentration (Figure 10).
Transformations
Once working antibiotic concentrations had been characterised for both antibiotics, transformations could be carried out. Addgene plasmid number 79813 was selected for transformation protocol optimisation due to its Pseudomonas origin of repolication and gentamicin resistance gene. Two minipreps were carried out on the plasmid containing E. coli strain, one of which was aliquoted and spun down giving three DNA solutions of varying DNA concentration (Table1).
Four electroporation experiments were carried out, one for each DNA solution and a negative where water was added in place of a DNA solution. Gentamicin resistant colonies formed for each of the DNA solutions with solution 1 giving the highest number of CFUs (Figure 11) and miniprep 3 the lowest (Figure 13). No colonies formed on agar inoculated with the negative control (Figure 14). Colony forming units obtained from each miniprep are displayed in Table 2.
Table 2. Colonies formed from electrocompetent Pseudomonas sp. inoculated with solutions containing Addgene plasmid #79813
An additional MIC experiment was carried out to characterise gentamicin resistance of the transformant (Figure 15). The transformant was resistant to gentamicin at the highest concentration tested (50 µg/ml).
New Part
A composite part containing the antibiotic resistance gene aadA, an anderson promoter, a strong RBS and a native terminator was designed. This part conferred resistance to streptomycin, the second antibiotic found to be active against Pseudomonas sp. This part was assembled into pBS1C3 for characterisation and submission to the registry. The Gibson assembly reaction mix is shown in Table 3.
Following assembly, chemically competent E. coli cells were transformed using each reaction mix. CFUs were obtained for both the streptomycin resistance Gibson assembly reaction mix (Figure 16) and the positive control (Figure 17). No colonies formed on agar inoculated with the negative control (Figure 18).
Following transformation, colonies were re-streaked on agar containing streptomycin (50 µg/ml) (Figure 19) confirming resistance and on agar containing chloramphenicol (25 µg/ml) as resistance was confirmed by the pBS1C3 backbone (Figure 20).
Streptomycin resistance of the transformed E. coli was compared to the wild type (Figure 21). The transformant was resistant to streptomycin at the highest concentration tested (64 µg/ml).
Conclusions
Pseudomonas sp. was found to be susceptible to two antibiotics, streptomycin and gentamicin. Using a Pseudomonas origin plasmid containing a gentamicin resistance gene electroporation protocols have been optimised for Pseudomonas sp. The new streptomycin resistance part confers strong resistance to streptomycin in E. coli.
Refrences & Attributions
Attributions: Frank Eardley and Lewis Tomlinson